Mark Gold Net Worth

The estimated Net Worth of Mark Stephen Gold is at least $4.28 Milión dollars as of 1 June 2022. Mark Gold owns over 3,036 units of Axogen stock worth over $4,056,708 and over the last 14 years he sold AXGN stock worth over $34,274. In addition, he makes $185,625 as Independent Director at Axogen.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Gold AXGN stock SEC Form 4 insiders trading

Mark has made over 21 trades of the Axogen stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 3,036 units of AXGN stock worth $40,318 on 1 June 2022.

The largest trade he's ever made was buying 83,682 units of Axogen stock on 22 August 2016 worth over $246,862. On average, Mark trades about 9,690 units every 112 days since 2011. As of 1 June 2022 he still owns at least 305,475 units of Axogen stock.

You can see the complete history of Mark Gold stock trades at the bottom of the page.

Mark Gold biography

Dr. Mark Stephen Gold serves as Independent Director of the Company. Dr. Gold has served as a member of our Board of Directors since September 30, 2011 and Axogen Corporation’s board of directors since July 2007. From 1990 until his retirement in June 2014, Dr. Gold was a Professor at the University of Florida College of Medicine’s McKnight Brain Institute and was recognized as a Distinguished Professor and Eminent Scholar and was Chairman of the Department of Psychiatry. He has also been recognized as the 17th University of Florida Distinguished Alumni Professor and served in that capacity for 4 years. Dr. Gold taught neuroanatomy and medical neuroscience for four decades and has been a pioneer in translational neuroscience research. He has been a consultant and senior advisor to banks and private equity and venture capital firms on medical devices, pharmaceuticals and health care services throughout his career. Dr. Gold was also a Founding Director of the Somerset Valley Bank and Somerset Valley Financial (Nasdaq: SVBF) from 1991 to 1999 which was sold to Fulton Financial Corporation. Dr. Gold is a Director of The Magstim Company Ltd., a United Kingdom based global leader in brain stimulation, nerve modulation, and intraoperative nerve monitoring. He was a Founding Director at Viewray, a public commercial stage MR-Guided Radiotherapy company specializing in Cancer treatment. Dr. Gold earned his M.D. from the University of Florida College of Medicine and his B.S. from Washington University in St. Louis.

What is the salary of Mark Gold?

As the Independent Director of Axogen, the total compensation of Mark Gold at Axogen is $185,625. There are 9 executives at Axogen getting paid more, with Eric Sandberg having the highest compensation of $1,113,440.

How old is Mark Gold?

Mark Gold is 71, he's been the Independent Director of Axogen since 2011. There are no older and 14 younger executives at Axogen.

What's Mark Gold's mailing address?

Mark's mailing address filed with the SEC is 13631 PROGRESS BOULEVARD, SUITE 400, ALACHUA, FL, 32615.

Insiders trading at Axogen

Over the last 14 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels a Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.

What does Axogen do?

it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.

Complete history of Mark Gold stock trades at Axogen a ViewRay

Axogen executives and stock owners

Axogen executives and other stock owners filed with the SEC include:

• Eric Sandberg,
  Chief Commercial Officer
• Karen Zaderej,
  Chairman of the Board, President, Chief Executive Officer
• Gregory Freitag,
  Director
• Angelo Scopelianos,
  Vice President - Research and Development
• Peter Mariani,
  Chief Financial Officer
• Maria Martinez,
  Chief Human Resource Officer
• Quentin Blackford,
  Independent Director
• Alan Levine,
  Independent Director
• Amy Wendell,
  Lead Independent Director
• Mark Gold,
  Independent Director
• Guido Neels,
  Independent Director
• Paul Thomas,
  Director
• Brad Ottinger,
  Chief Compliance Officer, General Counsel
• Isabelle Billet,
  Chief Strategy and Business Development Officer
• Mark Friedman,
  Vice President - Regulatory Affairs and Quality Assurance
• Erick DeVinney,
  Vice President - Clinical and Translational Sciences
• Mike Donovan,
  Vice President - Operations
• James E Deerfield Mgmt L.P....,
  
• John P Engels,
  Vice President
• Jamie Mark Grooms,
  Director
• Robert James Rudelius,
  Director
• Joseph M Mandato,
  Director
• Shawn F Mccarrey,
  SVP of Sales
• Lisa N Colleran,
  Director
• Jon S. Gingrich,
  Chief Commercial Officer
• Woodlands Fund Ix, L.P. Essex,
  10% owner
• Kevin Leach,
  Vice President Marketing
• Kathy Johnson Weiler,
  Director
• William P. Mr. Burke,
  Director
• Lee Robert Jr Johnston,
  Chief Financial Officer
• Jill F Schiaparelli,
  SVP, Bus. Strategy&Marketing
• John Frederick Harper,
  Director
• Bradley Jay Hedger,
  Vice President, Sales
• David K Hansen,
  VP Finance & Treasurer
• Michael Patrick Donovan,
  VP Operations
• Joseph A. Tyndall,
  Director
• John Johnson,
  Director
• Nir Naor,
  CFO
• Marc A Began,
  EVP and General Counsel
• Jens Kemp,
  Chief Marketing Officer
• Michael D Dale,
  CEO and President